David Nichols Recommends the Following Stocks: Inamed Corp. and Penwest Pharmaceuticals.
CHICAGO--(BUSINESS WIRE)--Jan. 17, 2003
Finding a profitable investment isn't that difficult when you know where to look. But, as everyone now knows, that's easier said than done. David Nichols gives readers a shove in the right direction, with a couple of recommendations that seem to be in the right place at the right time. Read his takes on Inamed Corp. (NASDAQ:IMDC) and Penwest Pharmaceuticals (Nasdaq:PPCO). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/
Here are the highlights from the Featured Expert column:
Plain and simple, we need a resolution to this Iraqi situation. Nichols' puzzlement over the potential outcome is exactly the same thing that tens of millions of other market participants are experiencing. Nobody knows. And basically, that has been -- and will continue to be -- the dominant market theme. As long as this uncertainty exists, it will be tough to make money on the long side.
Inamed Corp. (NASDAQ:IMDC) is advancing in the very fast-growing aesthetic "lifestyle" niche. With millions of affluent middle-aged Americans and Europeans looking unhappily in the mirror, and millions more headed inevitably toward middle age over the next 20 years (to be followed by their own children), Inamed is in the right place at the right time.
Inamed makes money in every product category, both in the U.S. and internationally. Total sales for the third quarter were $67 million, up 18% over last year, with earnings per share up 38%. The stock traded recently at $32; the market capitalization is a surprisingly low $703 million. Inamed has $58 million in cash, some of which it will need for upcoming product trials. It won't surprise Nichols if Inamed declares a dividend within the year.
Penwest Pharmaceuticals (Nasdaq:PPCO) develops drug products based on novel drug delivery technologies. It's developed an unusual new controlled-release technology called TIMERx. TIMERx is being used in an oxymorphone extended-release (ER) tablet by Endo Pharmaceuticals, who makes big-name pain-management drugs including Percocet and Lidoderm.
Penwest gets revenue from royalties, licensing arrangements, milestone payments, and from the purchase of formulated TIMERx material. Par for the course, third-quarter net loss was up slightly to $4.5 million, since research, development and clinical trials cost a bundle. Revenues were $11 million compared to last year's $9.8 million. It traded recently at $10.65. Market cap is a reasonable $163 million, and the high short interest should help to prop up the stock price.
Receive even more information on the above-mentioned companies, and get several more of David Nichols' recommendations, by clicking: http://featuredexpert3bw.zacks.com/
About Zacks Featured Experts
To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.
Recommendations from Featured Experts Highlighted in FREE Investment Newsletter
The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at:
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 17, 2003|
|Previous Article:||Corporate Profile for ADC, dated January 17, 2003.|
|Next Article:||Richard Moroney Recommends the Following Stocks: Duke Energy and Guidant.|